---
title: "Hanx Biopharmaceuticals partners with TwinEdge Bioscience on AI-driven HX009 development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291564800.md"
description: "Hanx Biopharmaceuticals has partnered with TwinEdge Bioscience for AI-driven development of its lead candidate HX009. TwinEdge will create digital twin models using patient data to simulate dose response and clinical performance, aiding patient selection and trial planning. HX009 is a bifunctional anti-PD-1/SIRPα fusion protein, with pivotal trials planned for EBV-positive non-Hodgkin lymphoma."
datetime: "2026-07-02T14:54:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291564800.md)
  - [en](https://longbridge.com/en/news/291564800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291564800.md)
generator: "portal-rs"
---

# Hanx Biopharmaceuticals partners with TwinEdge Bioscience on AI-driven HX009 development

-   Hanx Biopharmaceuticals entered an AI-driven drug development collaboration with Switzerland-based TwinEdge Bioscience focused on its lead candidate HX009. \* TwinEdge will build “digital twin” models using DLBCL patient-derived xenograft mouse data to simulate HX009’s dose response and potential clinical performance. \* Early work produced preliminary digital twin models, setting up integration of molecular data to support patient selection and clinical-trial planning. \* HX009 is a bifunctional anti-PD-1/SIRPα fusion protein; a pivotal trial is planned in EBV-positive non-Hodgkin lymphoma including EBV-positive DLBCL. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260702-12230285), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03378.HK](https://longbridge.com/en/quote/03378.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Hanx Biopharmaceuticals posts announcement on AI-driven drug discovery collaboration](https://longbridge.com/en/news/291919968.md)
- [Pierre & Vacances reports 462 million shares outstanding, 461.91 million voting rights as of Aug. 31, 2026](https://longbridge.com/en/news/297807375.md)
- [Alset AI Ventures Inc. GAAP EPS of $0.19](https://longbridge.com/en/news/297563122.md)
- [Security Risk Advisors Launches SCALR AI as a Free SOC AI Platform for Security Teams](https://longbridge.com/en/news/297523531.md)
- [Why the AI boom has become an election problem](https://longbridge.com/en/news/297766132.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**